Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Liver Neoplasms 2Glioma 2Glioblastoma 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1Adenoma, Liver Cell 1

Interventions

Specimen Handling 6Magnetic Resonance Spectroscopy 4Gemcitabine 3Biopsy 3eribulin 2cabozantinib 2atezolizumab 2pembrolizumab 1erdafitinib 1enfortumab vedotin 1carotuximab 1avelumab 1Watchful Waiting 1Platinum 1Observation 1Nivolumab 1Lenalidomide 1Ipilimumab 1Interleukin-7 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Contrast Media 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 1Bortezomib 1Bevacizumab 1Arsenic Trioxide 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ureteral Neoplasms × carotuximab × Clear all
NCT01328574 2017-01-13

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
13 enrolled 15 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡